J.C. Galceran - Hospital Clínico de Salamanca, Institut Catala d'Oncologia

基本信息

浏览量：3

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 9 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

127P Clinical Utility of Circulating Tumor DNA (ctdna) Next Generation Sequencing (NGS) to Inform Treatment Decisions for Patients (pts) with Advanced Solid Tumors

D.A. Gomez Puerto, A. Rossi,A. Hernando Calvo, J.M. Ucha Hermida, M. Gómez,J. Matito,M. Vila-Casadesús,D. Morchón Araujo,R. Dienstmann,J.C. Galceran,D.G. Illescas,T. Macarulla Mercade,E. Garralda,C. Saura Manich,M.E. Elez Fernandez,E. Felip,J. Tabernero,A. Vivancos

Annals of Oncology (2024): S265-S266

引用0浏览0引用

123P Pan-cancer Homologous Recombination Deficiency (HRD) Evaluation in Patients Enrolled in a Routine Molecular Screening Program

P. Romero-Lozano,A. Hernando Calvo, E. Castillo, D.G. Lo Giacco,M. Vila-Casadesús, M. Gómez, G. Buono, V. Bach, M. Pereira, A. Onieva, A. Martin,J. Matito,P.G. Nuciforo,E. Garralda,E. Felip,C. Saura Manich,J.C. Galceran,C. Garcia Duran,J. Tabernero,A. Vivancos

Annals of Oncology (2024): S263

引用0浏览0引用

1637P Efficacy of Talazoparib and Enzalutamide in Mcrpc Patients Previously Treated with Androgen Receptor Pathway Inhibitors (ARPI) or Docetaxel: Post Hoc Analysis from Both Cohorts in TALAPRO-2 Study

N. Agarwal,A.A. Azad,J.C. Galceran,A.P. Fay,N. Matsubara, C. Szczylik,U. De Giorgi,J.Y. Joung,P.C. Fong,E. Voog,R.J. Jones,N.D. Shore,C. Dunshee,S. Zschäbitz,J. Oldenburg,X. Lin,D. Laird, M. Kalac, D. Kennedy,K. Fizazi

Annals of Oncology (2024): S987-S988

引用0浏览0引用

1601P First Results from ZZFIRST: A Randomized Phase II Trial of Enzalutamide (EZ) with or Without Talazoparib (TALA) in Metastatic Hormone-Naïve Prostate Cancer (Mhnpc)

J. Mateo,E. Castro,A. Rodriguez-Vida,B. Mellado Gonzalez,D.E. Castellano Gauna,M.A. Climent Duran,A. Borque Fernando,M.I. Sáez,B. Herrera Imbroda,A. Font Pous,D. Lorente,J. Planas Morin,A. Vivancos, J. Cardona,J.A. Guerrero, J. Perez-Escuredo, A.J. Zurita Saavedra,J.C. Galceran

Annals of Oncology (2024): S966

引用0浏览0引用

1626P Incidence of Hematologic Toxicities in the Homologous Recombination Repair (Hrr)-Deficient Population of the TALAPRO-2 Trial and Their Potential Association with Germline Vs Somatic Origin of HRR Gene Alterations

A.A. Azad,N. Agarwal,N.D. Shore,J.C. Galceran,A.P. Fay,N. Matsubara,F. Saad,U. De Giorgi,J.Y. Joung,P.C. Fong,S. Zschäbitz,J.M. Piulats Rodriguez,S.M. Yip, G. Liu,L. DeAnnuntis,X. Lin,D. Laird, M. Kalac,K. Fizazi

Annals of Oncology (2024): S981-S982

引用0浏览0引用

457P Progression-free Survival 2 (PFS2) As a Surrogate for Overall Survival in a Multicentric Real-World Data Cohort of Glioblastoma (GBM)

J.G. Yaringaño Cerna,O. Mirallas,D.A. Gomez Puerto,G. Velilla,V. Navarro Garces,T. Gorría Puga, A.M. Monino,M.Á. Vaz-Salgado,D. Lopez-Valbuena,A. Hernandez Gonzalez,M. Aguado Sorolla,M. Gonzalez Rodriguez,M. Martínez-García,J.C. Galceran,C. Balana,G. Villacampa,R. Dienstmann,E. Pineda,J.M. Sepúlveda,M. Vieito

Annals of Oncology (2024): S412-S413

引用0浏览0引用

LBA67 Cabozantinib (C) Plus Atezolizumab (A) Versus 2nd Novel Hormonal Therapy (NHT) in Patients (pts) with Metastatic Castration-Resistant Prostate Cancer (mcrpc): Final Overall Survival (OS) Results of the Phase III, Randomized, CONTACT-02 Study

N. Agarwal,A.A. Azad,J.C. Galceran,N. Matsubara, S. Oudard, F. Saad, A.S. Merseburger, A. Soares,B.A. McGregor,B. Zurawski,M. Tsiatas,S. North,E. Bournakis,L. Antonuzzo,D.S. Williamson, L. Evilevitch, A. Simmons,R. Ferraldeschi, P. Nandoskar,S.K. Pal

Annals of Oncology (2024): S1256-S1257

引用0浏览0引用

1479P Use of Rescue Opioids and Pain Control after Ketamine Initiation in Refractory Cancer Pain: A Multicentric Observational Study

P. Gallardo Melo,F. Bosma, A. Urueña, J. Garrillo Cepeda,J. Aguilar-Company,J.C. Tapia, J. Serna i Mont-Ros, L. Maciel Bravo,B. Martin Cullell,O. Mirallas, C. Gianella Blanco,C. Salva de Torres, S. Martinez Peralta,M. Aguado Sorolla, B. Alonso Martínez,S. Eremiev,M. Roca,S. Serradell,J.C. Galceran,P. Gomez Pardo

Annals of Oncology (2024): S913-S914

引用0浏览0引用

A Single-Arm Phase II Trial to Evaluate the Combination of Cetuximab Plus Docetaxel, Cisplatin, and 5-Fluorouracil (TPF) As Induction Chemotherapy (IC) in Patients (pts) with Unresectable SCCHN

R. Mesia,S. Vazquez,J. J. Grau,J. A. Garcia-Saenz,C. Bayona,J. C. Galceran,A. Irigoyen,A. Lozano,M. Manos,J. J. Cruz

Journal of clinical oncologyno. 15_suppl (2009): 6015-6015

引用17浏览0引用

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn